Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 683

• Price / Volume Information    Yesterday's Closing Price: $184.74 Daily Weekly Monthly 20 Day Moving Average: 496,689 shares Shares Outstanding: 50.41 (millions) Market Capitalization: $9,313.23 (millions) Beta: 0.40 52 Week High: $191.50 52 Week Low: $86.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.31% -2.39% 12 Week 22.36% 21.14% Year To Date 1.15% 0.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One World Trade Center 22nd Floor - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://www.axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman of the Board Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information Axsome Therapeutics, Inc. (CORR.) Axsome Therapeutics, Inc. (RSPI) Axsome Therapeutics, Inc. (CGXP) Axsome Therapeutics, Inc. (BGEN) Axsome Therapeutics, Inc. (GTBP) Axsome Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/23/26 Share - Related Items Shares Outstanding: 50.41 Most Recent Split Date: (:1) Beta: 0.40 Market Capitalization: $9,313.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 44.97% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/23/26

• Fundamental Ratios P/E Current FY Estimate: 536.18 Trailing 12 Months: - PEG Ratio: 11.92 Price Ratios Price/Book: 126.32 Price/Cash Flow: - Price / Sales: 16.59 EPS Growth vs. Year Ago Period: 29.85% vs. Previous Quarter: -2.17% Sales Growth vs. Year Ago Period: 63.22% vs. Previous Quarter: 13.96% ROE 12/31/25 - - 09/30/25 - -277.31 06/30/25 - -283.22 ROA 12/31/25 - - 09/30/25 - -28.81 06/30/25 - -33.06 Current Ratio 12/31/25 - - 09/30/25 - 1.57 06/30/25 - 1.57 Quick Ratio 12/31/25 - - 09/30/25 - 1.50 06/30/25 - 1.51 Operating Margin 12/31/25 - - 09/30/25 - -31.75 06/30/25 - -39.50 Net Margin 12/31/25 - - 09/30/25 - -40.90 06/30/25 - -49.88 Pre-Tax Margin 12/31/25 - - 09/30/25 - -41.05 06/30/25 - -50.05 Book Value 12/31/25 - - 09/30/25 - 1.46 06/30/25 - 1.46 Inventory Turnover 12/31/25 - - 09/30/25 - 2.46 06/30/25 - 2.61 Debt-to-Equity 12/31/25 - - 09/30/25 - 1.66 06/30/25 - 1.66 Debt-to-Capital 12/31/25 - - 09/30/25 - 62.39 06/30/25 - 62.41

Powered by Zacks Investment Research ©